Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04313634 · ClinicalTrials.gov registry record · Phase 2

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

A Phase 2 study of Healthy, sponsored by Sundeep Khosla, M.D..

Completed
Registry status
Phase 2
Development phase
74
Enrollment target
1
Study location

NCT04313634 is a Phase 2 study of Healthy that has completed, run by Sundeep Khosla, M.D.. The registered enrollment target is 74 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04313634, a Phase 2 study of Healthy, has completed, sponsored by Sundeep Khosla, M.D..

COMPLETED
Registry status
Phase 2
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.

Conditions Studied

Healthy

Interventions

  • DRUG Dasatinib
  • DRUG Fisetin
  • DRUG Quercetin

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2020-06-09
Est. Completion 2023-06-06
Phase Phase 2

Sponsor

Sundeep Khosla, M.D.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04313634

The ClinicalTrials.gov registry entry for NCT04313634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is Sundeep Khosla, M.D., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Dasatinib is the first listed.

NCT04313634 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04313634 about?

NCT04313634 is a clinical study titled "Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans". To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.

What is the current status of trial NCT04313634?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2020-06-09. Estimated completion is 2023-06-06.

What conditions does trial NCT04313634 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04313634?

The interventions under investigation include: Dasatinib (DRUG), Fisetin (DRUG), Quercetin (DRUG).

Who is sponsoring clinical trial NCT04313634?

This trial is sponsored by Sundeep Khosla, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04313634 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.